CTOs on the Move

Capsida

www.capsida.com

 
We are a biotechnology company creating a new class of targeted gene therapies for debilitating and life-threatening genetic disorders in both central nervous system (CNS) and non-CNS indications. Current gene therapy approaches have shown dramatic efficacy in several rare diseases but are hindered by imprecise targeting. The inability to selectively transduce specific cells and tissues effectively drives administration of higher doses and resulting safety liabilities. We are addressing these concerns with our proprietary adeno-associated virus (AAV) engineering platform that generates capsids optimized to target specific tissues and cells in the disease organ while limiting transduction of tissues and cells not relevant ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.capsida.com
  • 1290 Rancho Conejo Boulevard
    Newbury Park, CA USA 91320
  • Phone: 310.403.8951

Executives

Name Title Contact Details
Nick Goeden
Chief Technology Officer Profile

Funding

Capsida raised $50M on 04/29/2021

Similar Companies

Istari Oncology

Istari Oncology, Inc. is a clinical-stage biotechnology company focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. The company was founded by Darell Bigner, MD, and Matthias Gromeier, MD, of Duke University Medical Center in 2016. Both are leaders in their respective research fields of virology, immunology, monoclonal development and clinical medicine, particularly in the treatment of brain tumors.

Evidence CPR

EVIDENCE takes care of continuous education of investigators in clinical trials and takes every effort to help them keep a high level of practical knowledge of GCP (Good Clinical Practice) and other aspects of clinical trails. EVIDENCE offers GCP courses

Enzymotec

Enzymotec develops and manufactures nutritional ingredients and medical foods, driven by a deep core of cutting-edge, proprietary technologies. Since its establishment in 1998, the company has enjoyed accelerated growth, generating impressive sales worldwide, by launching a diverse portfolio of innovative products. Our two business segments leverage our lipid-related expertise: Nutrition and Pharma.   Enzymotec's diverse range of products span the entire human life-cycle - from infancy to old age, providing key ingredients for use in infant formula and nutritional supplements, as well as branded medical foods.   Enzymotec's multi-disciplinary team, including scientists, engineers and business development professionals, have an outstanding track-record in turning advanced lipid science into commercially attractive, nutritional solutions, constantly enriching our unique cluster of technology and expertise.

Ceribell

Ceribell is a fast growing venture-backed medical device start-up company founded by two faculty members at Stanford University. Our primary mission is to improve neurological care for emergency and ICU patients. Ceribell is focused on making EEG widely accessible, more efficient, and more cost-effective to improve the diagnosis and treatment of patients at risk for seizures. The System can be set up by any healthcare provider within minutes. Now with Clarity, Ceribell offers 24/7 continuous bedside EEG monitoring and alert.

Primmune Therapeutics

Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Our goal is to improve the response rate of patients to current and future immunotherapy medicines.